Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs 22nd Century Group Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while 22nd Century Group Inc trades at $4.19 (market cap $1.45M). Which is the better fit depends on your goals.
| BIL | XXII | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $91.77 | $1.47K |
52-Week Low | $91.27 | $3.90 |
Market Cap | — | $1.45M |
Enterprise Value | — | -$6.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.50 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The ETF maintains consistent dividend payments of $0.27 per share. Market sentiment is influenced by Federal Reserve rate hike speculation and competition among cash ETFs, as noted in recent financial news.
The outlook for BIL hinges on interest rate trends, with potential upside if the Fed hikes rates, boosting short-term Treasury yields. Risks include prolonged low-rate environments and investor shifts to higher-yielding alternatives. Current technical weakness suggests caution, but the ETF's stability and dividends offer defensive appeal in volatile markets.
XXII trades at $4.10, down 3.07% today, with a bearish technical signal from moving averages. The company shows severe financial distress with a negative gross profit margin of -52.19% and net income margin of -65.76% for 2025. Recent news highlights expansion of VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. A 20:1 reverse stock split occurred on June 12, 2026, to adjust share structure.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is 75% buy-rated. Investment opportunity hinges on successful commercialization of VLN products and FDA regulatory renewals. Key risks include execution challenges, intense competition, and reliance on financing to sustain operations amid negative cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
